RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

Rapid Therapeutic Science Laboratories, Inc.

RTSL

US7534312043

Pharmaceuticals

Delayed OTC Markets Other stock markets 17:34:46 03/05/2024 BST			5-day change	1st Jan Change
0.005 ^USD	0.00%		0.00%	+21.95%

2023	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
2023	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2020

November 09, 2020 at 05:05 pm

Rapid Therapeutic Science Laboratories, Inc. announced earnings results for the second quarter ended September 30, 2020. For the second quarter, the company announced sales was USD 1,629. Net loss was USD 640,536 compared to USD 67,673 a year ago. For the half year, sales was USD 130,916. Net loss was USD 1.206 million compared to USD 136,746 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.11 a year ago.

Latest news about Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	29/03/23	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	30/05/22	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	11/05/22	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16/03/22	CI
Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	15/03/22	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	27/01/22	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	17/01/22	CI
Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	11/11/21	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	10/11/21	CI
Rapid Therapeutic Science Laboratories Appoints Justin Suggs to Its Board of Directors	02/11/21	CI
Rapid Therapeutic Science Laboratories, Inc. Appoints Henry A. Punzi, as A Member of the Board of Directors	25/08/21	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	11/08/21	CI
Rapid Therapeutic Science Laboratories, Inc. Appoints J. Scott Suggs as Member of the Board of Directors and as Chairperson (And Sole Member) of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee	05/08/21	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $1.65 million in funding from Armistice Capital LLC	03/08/21	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it expects to receive $1.65 million in funding from Armistice Capital LLC	31/07/21	CI
Rapid Therapeutic Finalizes Lab Work on Pharmaceutical Formulas	10/06/21	CI
Rapid Therapeutic Prepares to File Investigational New Drug Application for its CBD Metered Dose Inhaler with FDA	02/06/21	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	14/05/21	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Nine Months Ended December 31, 2020	16/03/21	CI
Empower : Holley to Go Public in Merger With Bank-Check Company Empower	12/03/21	MT

Chart Rapid Therapeutic Science Laboratories, Inc.

Duration

Period

Chart Rapid Therapeutic Science Laboratories, Inc.

More charts

Company Profile

Rapid Therapeutic Science Laboratories, Inc. is a biopharmaceutical company. The Company is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company has developed a method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more patent pending pharmaceutical-grade cannabinoid compounds. It has developed and is continuing to develop a series of complementary products in addition to its inhaler. It is also focusing on manufacturing its own branded MDI under the nhaler brand name.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	+21.95%	94.93K
DONG-E-E-JIAO CO.,LTD.	+45.15%	6.34B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-14.00%	4.61B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+9.54%	3.39B
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.99%	3.29B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.03%	2.02B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-6.97%	1.73B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.31%	1.67B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+50.00%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-10.61%	1.59B